{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:14:37Z","timestamp":1785338077594,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011676","name":"Elekta Corporate Giving","doi-asserted-by":"publisher","award":["X-V0.47"],"award-info":[{"award-number":["X-V0.47"]}],"id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cyto.2025.156980","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:33:13Z","timestamp":1750163593000},"page":"156980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["ATM and ATR inhibition increases radiosensitivity and cGAS-STING activation in prostate cancer"],"prefix":"10.1016","volume":"193","author":[{"given":"Nina","family":"van Campen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera E.","family":"Mekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike W.","family":"Looman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lune","family":"van den Bogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther D.","family":"Kers-Rebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenny J.M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Fern\u00e1ndez","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Schuurmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Jan","family":"Smeenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Ansems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gosse J.","family":"Adema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cyto.2025.156980_bb0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate Cancer epidemiology and risk factors-a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.cyto.2025.156980_bb0010","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10552-021-01484-4","article-title":"Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States","volume":"32","author":"Wallace","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Rebecca Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.cyto.2025.156980_bb0020","doi-asserted-by":"crossref","first-page":"769","DOI":"10.5534\/wjmh.220200","article-title":"Systemic therapies for metastatic castration-resistant prostate Cancer: an updated review","volume":"41","author":"Hatano","year":"2023","journal-title":"World J. Mens Health"},{"key":"10.1016\/j.cyto.2025.156980_bb0025","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate Cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.cyto.2025.156980_bb0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.cyto.2025.156980_bb0035","first-page":"827","article-title":"Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression","volume":"23","author":"Johnke","year":"2009","journal-title":"In Vivo"},{"key":"10.1016\/j.cyto.2025.156980_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.cyto.2025.156980_bb0045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102611118","article-title":"Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads","volume":"118","author":"Lussier","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the tumor inflammation signature (TIS): results from the Cancer genome atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.cyto.2025.156980_bb0055","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.cyto.2025.156980_bb0060","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate Cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cyto.2025.156980_bb0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrg2380","article-title":"Single-strand break repair and genetic disease","volume":"9","author":"Caldecott","year":"2008","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41420-024-02059-3","article-title":"Inhibition of key DNA double strand break repair protein kinases enhances radiosensitivity of head and neck cancer cells to X-ray and proton irradiation","volume":"10","author":"Fabbrizi","year":"2024","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.cyto.2025.156980_bb0075","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cyto.2025.156980_bb0080","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate Cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.cyto.2025.156980_bb0085","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Andrew","year":"2017","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.cyto.2025.156980_bb0090","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cyto.2025.156980_bb0095","doi-asserted-by":"crossref","first-page":"v881","DOI":"10.1093\/annonc\/mdz394.039","article-title":"LBA12_PR - PROfound: phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations","volume":"30","author":"Hussain","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cyto.2025.156980_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy284.002","article-title":"Preliminary results from TRITON2: a phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations","volume":"29","author":"Abida","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.cyto.2025.156980_bb0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential response to Olaparib treatment among men with metastatic castration-resistant prostate Cancer harboring BRCA1 or BRCA2 versus ATM mutations","volume":"76","author":"Marshall","year":"2019","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.cyto.2025.156980_bb0110","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate Cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.cyto.2025.156980_bb0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.molcel.2007.11.015","article-title":"The DNA damage response: ten years after","volume":"28","author":"Harper","year":"2007","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.cyto.2025.156980_bb0120","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer","volume":"80","author":"Shahrzad Rafiei","year":"2020","journal-title":"Cancer Res."},{"issue":"5625","key":"10.1016\/j.cyto.2025.156980_bb0125","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.cyto.2025.156980_bb0130","doi-asserted-by":"crossref","first-page":"8395","DOI":"10.1074\/jbc.RA119.008154","article-title":"Common motifs in ETAA1 and TOPBP1 required for ATR kinase activation","volume":"294","author":"Thada","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.cyto.2025.156980_bb0135","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","article-title":"Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint","volume":"14","author":"Liu","year":"2000","journal-title":"Genes Dev."},{"issue":"7729","key":"10.1016\/j.cyto.2025.156980_bb0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-018-0629-6","article-title":"Nuclear cGAS suppresses DNA repair and promotes tumorigenesis","volume":"563","author":"Liu","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0145","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.apsb.2021.03.043","article-title":"DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS\u2013STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"22","key":"10.1016\/j.cyto.2025.156980_bb0150","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154229","article-title":"H3.3-G34 mutations impair DNA repair and promote cGAS\/STING-mediated immune responses in pediatric high-grade glioma models","volume":"132","author":"Haase","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0155","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1038\/s41467-021-26240-9","article-title":"A non-canonical, interferon-independent signaling activity of cGAMP triggers DNA damage response signaling","volume":"12","author":"Banerjee","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2020.11.004","article-title":"MLH1 deficiency-triggered DNA Hyperexcision by exonuclease 1 activates the cGAS-STING pathway","volume":"39","author":"Guan","year":"2021","journal-title":"Cancer Cell"},{"issue":"6121","key":"10.1016\/j.cyto.2025.156980_bb0165","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cyto.2025.156980_bb0170","doi-asserted-by":"crossref","unstructured":"Tatsuya Saitoh, N.F., Takuya Hayashi, Shizuo Akira, Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. PNAS, 2009. 106(49): p. 20842\u201320846.","DOI":"10.1073\/pnas.0911267106"},{"issue":"6121","key":"10.1016\/j.cyto.2025.156980_bb0175","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.1229963","article-title":"Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA","volume":"339","author":"Wu","year":"2013","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.cyto.2025.156980_bb0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41419-024-06911-3","article-title":"ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC class I","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2025.156980_bb0185","doi-asserted-by":"crossref","unstructured":"Taniguchi, H., et al., ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Sci. Adv.. 10(39): p. eado4618.","DOI":"10.1126\/sciadv.ado4618"},{"issue":"19\u201320","key":"10.1016\/j.cyto.2025.156980_bb0190","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1101\/gad.351084.123","article-title":"ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy","volume":"37","author":"Wang","year":"2023","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1535-7163.MCT-24-0289","article-title":"Riluzole enhancing anti-PD-1 efficacy by activating cGAS\/STING signaling in colorectal cancer","volume":"24","author":"Liang","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.cyto.2025.156980_bb0200","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139333","article-title":"ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation","volume":"131","author":"Hu","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1667\/RR3486.1","article-title":"Computational methods for analysis of foci: validation for radiation-induced \u03b3-H2AX foci in human cells","volume":"165","author":"Wilfried","year":"2006","journal-title":"Radiat. Res."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0210","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/labinvest.3700208","article-title":"Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes","volume":"85","author":"de Kok","year":"2005","journal-title":"Lab. Investig."},{"issue":"4","key":"10.1016\/j.cyto.2025.156980_bb0215","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"22","key":"10.1016\/j.cyto.2025.156980_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228877","article-title":"The impact of radiation-induced DNA damage on cGAS-STING-mediated immune responses to Cancer","volume":"21","author":"Storozynsky","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.cyto.2025.156980_bb0225","first-page":"5194","article-title":"Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase","volume":"59","author":"Garzotto","year":"1999","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.cyto.2025.156980_bb0230","doi-asserted-by":"crossref","first-page":"23262","DOI":"10.1074\/jbc.M503701200","article-title":"Down-regulation of ATM protein sensitizes human prostate Cancer cells to radiation-induced apoptosis*","volume":"280","author":"Truman","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.cyto.2025.156980_bb0235","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.bbabio.2009.06.003","article-title":"Hypoxia and the metabolic phenotype of prostate cancer cells","volume":"1787","author":"Higgins","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1535-7163.MCT-09-0486","article-title":"Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells","volume":"9","author":"Mishra","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.cyto.2025.156980_bb0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2012.08.032","article-title":"Potentiation of inflammatory CXCL8 Signalling sustains cell survival in PTEN-deficient prostate carcinoma","volume":"64","author":"Maxwell","year":"2013","journal-title":"Eur. Urol."},{"issue":"5308","key":"10.1016\/j.cyto.2025.156980_bb0250","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate Cancer","volume":"275","author":"Li","year":"1997","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.cyto.2025.156980_bb0255","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-14-3502","article-title":"Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM","volume":"75","author":"McCabe","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010079","article-title":"ATM kinase inhibition preferentially Sensitises PTEN-deficient prostate tumour cells to Ionising radiation","volume":"13","author":"Hanna","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.cyto.2025.156980_bb0265","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/1078-0432.CCR-11-2189","article-title":"PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy","volume":"18","author":"Fraser","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.cyto.2025.156980_bb0270","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.cyto.2025.156980_bb0275","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-07-5164","article-title":"Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing","volume":"14","author":"Sfanos","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.cyto.2025.156980_bb0280","doi-asserted-by":"crossref","first-page":"492","DOI":"10.18632\/aging.204487","article-title":"Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death","volume":"15","author":"Chiu","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"10.1016\/j.cyto.2025.156980_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007474","article-title":"ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models","volume":"11","author":"Jin","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"14","key":"10.1016\/j.cyto.2025.156980_bb0290","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104036","article-title":"ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways","volume":"39","author":"Feng","year":"2020","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.cyto.2025.156980_bb0295","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.cyto.2025.156980_bb0300","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate Cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.cyto.2025.156980_bb0305","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2\u20323\u2019-cGAMP by ENPP1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"10.1016\/j.cyto.2025.156980_bb0310","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.immuni.2022.08.006","article-title":"ABCC1 transporter exports the immunostimulatory cyclic dinucleotide cGAMP","volume":"55","author":"Maltbaek","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2025.156980_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150705","article-title":"cGAMP the travelling messenger","volume":"14","author":"Blest","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2025.156980_bb0320","first-page":"184","article-title":"Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity","volume":"1","author":"Carozza","year":"2020","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0325","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1038\/s41598-021-86644-x","article-title":"cGAS-STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells","volume":"11","author":"Suter","year":"2021","journal-title":"Sci. Rep."},{"issue":"764","key":"10.1016\/j.cyto.2025.156980_bb0330","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abq5389","article-title":"Stress signaling boosts interferon-induced gene transcription in macrophages","volume":"15","author":"Boccuni","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cyto.2025.156980_bb0335","doi-asserted-by":"crossref","unstructured":"Raman, M., et al., TAO kinases mediate activation of p38 in response to DNA damage. EMBO J., 2007. 26(8): p. 2005\u20132014-2014.","DOI":"10.1038\/sj.emboj.7601668"},{"key":"10.1016\/j.cyto.2025.156980_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1138920","article-title":"Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases","volume":"14","author":"Eek Mariampillai","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156980_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111434","article-title":"Molecular mechanism of RIPK1 and caspase-8 in homeostatic type I interferon production and regulation","volume":"41","author":"Wang","year":"2022","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.cyto.2025.156980_bb0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.semradonc.2019.12.009","article-title":"Type I interferon response in radiation-induced anti-tumor immunity","volume":"30","author":"Zhang","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.cyto.2025.156980_bb0355","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nucmedbio.2021.03.009","article-title":"Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer","volume":"96-97","author":"Staniszewska","year":"2021","journal-title":"Nucl. Med. Biol."},{"issue":"2","key":"10.1016\/j.cyto.2025.156980_bb0360","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced prostate Cancer with ATM loss: PARP and ATR inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.cyto.2025.156980_bb0365","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s42764-020-00011-0","article-title":"ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738","volume":"1","author":"Jette","year":"2020","journal-title":"Genome Instab. Dis."},{"issue":"12","key":"10.1016\/j.cyto.2025.156980_bb0370","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:50:46Z","timestamp":1752601846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":74,"alternative-id":["S1043466625001279"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156980","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATM and ATR inhibition increases radiosensitivity and cGAS-STING activation in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"156980"}}